Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...

The results go a long way to firming up sentiment about Enhertu, which had been widely tipped to become a multibillion-dollar brand before the ILD issue dulled some of its lustre. Much of that ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

Enhertu significantly improves overall survival in HER2-positive metastatic gastric cancer compared to ramucirumab and paclitaxel. DESTINY-Gastric04 is the first phase 3 trial showing Enhertu's ...

AstraZeneca’s Enhertu (trastuzumab deruxtecan) led the market among new drugs, followed by Sun Pharma, which generated Rs 50 crore from 18 brands, and Dr. Reddy’s, which recorded Rs 45 crore ...

Enhertu, an oncology drug by AstraZeneca, led new drug sales in 2024 with Rs 58 crore, reflecting rising cancer cases. Over 3,100 new brands collectively earned Rs 1,097 crore, with significant ...

Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer, expanding treatment options for these patients. DESTINY-Breast06 trial showed Enhertu reduced disease progression ...

Daiichi Sankyo and AstraZeneca’s (AZN) Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic ...

"Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...